Recent News

August 10, 2021
Sydnexis Secures $45 Million Series B
Financing Led by Visionary Ventures and Bluestem Capital
Read More
May 15, 2021
Sydnexis Completes Enrollment in Phase 3 Clinical Trial
See more at ClinicalTrials.gov.
Read More
April 10, 2021
Sydnexis Executes Exclusive License with Santen
Santen SA and Sydnexis Inc. announce the signing of an exclusive licensing agreement for SYD-101.
Read More
January 27, 2020
Sydnexis Joins the Board of GMAC
GMAC’s mission is to promote public awareness of childhood myopia as a treatable disease
Read More
May 2, 2019
Sydnexis Announces First Patients in Phase 3 Clinical Trial
Announcing the Enrollment of First Patients in Phase 3 Myopia STAAR Study of SYD-101 in Children
Read More